Remission in trials of ulcerative colitis: What does it mean?

Practical Gastroenterology

Volumn 30, Issue 12, 2006, Pages 17-20

  Travis, Simon ^a   Dinesen, Lotte ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; MESALAZINE; PLACEBO; STEROID;

CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION; DISEASE ACTIVITY; DRUG EFFICACY; ENDOSCOPY; HEALTH CARE PERSONNEL; HUMAN; OBSERVER VARIATION; PHYSICIAN; RECTUM HEMORRHAGE; REMISSION; REVIEW; SCORING SYSTEM; ULCERATIVE COLITIS;

EID: 33845937641     PISSN: 02774208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (10)

1. Kornbluth A, Sachar DB. Ulcerative Colitis practice guidelines in adults (update): American College of Gastroenterology, practice parameters committee. Am J Gastroenterol, 2004; 99: 1371-1385.
2. Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: Analysis of changes in disease activity over years. Gastroenterology, 1994; 107: 3-11.
3. Langholz E, Munkholm P, Davidsen M, Binder V. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology, 1992; 103: 1444-1451.
4. D'Haens G, Sandborn WJ, Feagan B, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology, 2006 (in press).
5. Hanauer SB, Sandborn WJ, Archambault A, Dallaire C, Yacyshyn B, Regalli G. Efficacy and safety of Asacol 4.8 g/day (800 mg tablet) compared with 2.4 g/day (400 mg tablet) in treating moderately active Ulcerative Colitis. Can J Gastroenterol, 2006; 20 (Suppl 7):A 148.
6. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol, 2005; 100: 2478-2485.
7. Katz S, Kane S, Higgins P, Eusebio R, Yacyshyn B. Different Definitions of Remission for Ulcerative Colitis Result in Large Variations of Clinical Outcome Scores. Gastroenterology, 2006; 130 Suppl 2:A-482.
8. Rutgeerts P, Sandborn WJ, Feagan BG, et al Infliximab for induction and maintenance therapy for ulcerative colitis. NEJM, 2005; 353: 2462-2476.
9. Baron JH, Connell AM, Lennard-Jones J. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J, 1964; 5375: 89-92.
10. Travis SPL, Cooney R, Dunmon P, et al. Conduct of clinical trials in ulcerative colitis: impact of independent scoring of endoscopic severity on results of a randomised controlled trial with a peptide and 5ASA. Am J Gastroenterol, 2006 (abstract presented at ACG)